Literature DB >> 2580900

Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.

T Kalland, G Alm, T Stålhandshe.   

Abstract

The quinoline-3-carboxamide LS 2616 administered to mice in drinking water increased spontaneous cytotoxicity against YAC-1 cells in a dose-dependent manner. The enhancement of spontaneous cytotoxicity was found to be mediated by NK cells, as judged by their lack of adherence to nylon wool columns, relative resistance to treatment with antibodies to Thy-1.2 and complement, and almost total abrogation after depletion of asialo-GM1+ cells. Enhancement of NK activity was evident after 2 days of treatment, was maximal after 4 days, and remained elevated during the 14-day exposure period studied. NK activity returned to control levels 4 days after cessation of treatment. NK activity was significantly increased in spleen, peripheral blood, lymph nodes, and bone marrow of LS 2616-treated mice, while activity in peritoneal exudate cells and thymus remained low. LS 2616 was able to elevate NK activity in several mouse strains studied, including mice homozygous for the beige gene. Serum interferon levels were not increased during treatment with LS 2616. Combined injection of the interferon inducer Poly I:C and LS 2616 did not increase NK activity above that of animals injected with Poly I:C alone. However, Poly I:C, in contrast to LS 2616, increased NK activity in peritoneal exudate cells. Studies at the single cell level revealed that LS 2616 increased NK activity by increasing the number of lytically active cells via recruitment of new target-binding cells and not by increasing the lytic activity of pre-existing binders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580900

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor.

Authors:  A Parenti; S Donnini; L Morbidelli; H J Granger; M Ziche
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 2.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Generation of natural killer cells from bone marrow precursors in vitro.

Authors:  T Kalland
Journal:  Immunology       Date:  1986-04       Impact factor: 7.397

4.  [Anti-angiogenesis: a new approach to tumor therapy?].

Authors:  D Schiefer; C Gottstein; V Diehl; A Engert
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 5.  The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.

Authors:  John T Isaacs
Journal:  Expert Opin Investig Drugs       Date:  2010-10       Impact factor: 6.206

6.  Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis.

Authors:  P Hutchings; G Hedlund; K Dawe; S Howlett; A Cooke
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

7.  Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.

Authors:  D J Gross; H Sidi; L Weiss; T Kalland; E Rosenmann; S Slavin
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

8.  Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

Authors:  D M Karussis; D Lehmann; S Slavin; U Vourka-Karussis; R Mizrachi-Koll; H Ovadia; T Kalland; O Abramsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

9.  Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

Authors:  A Tarkowski; K Gunnarsson; T Stålhandske
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

10.  Stimulation of wound healing by the immunomodulator LS-2616 (Linomide).

Authors:  J Lepistö; M Laato; J Niinikoski; C Lundberg; B Gerdin
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.